News & Updates

Antihypertensive drugs tied to HCC risk in MASLD with cirrhosis
Antihypertensive drugs tied to HCC risk in MASLD with cirrhosis
27 Nov 2024 byStephen Padilla

Patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and cirrhosis who are taking antihypertensive medications, including calcium channel blockers (CCBs) and angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs), are at increased risk of developing hepatocellular carcinoma (HCC), suggests a study.

Antihypertensive drugs tied to HCC risk in MASLD with cirrhosis
27 Nov 2024
Presence of mVI/S predicts HCC recurrence after liver resection
Presence of mVI/S predicts HCC recurrence after liver resection
26 Nov 2024
Is ChatGPT ready to give CRC screening recommendations?
Is ChatGPT ready to give CRC screening recommendations?
20 Nov 2024 byStephen Padilla

The performance of ChatGPT in determining appropriate colorectal cancer (CRC) screening recommendations is relatively poor, with inconsistent responses in several questions, reports a study.

Is ChatGPT ready to give CRC screening recommendations?
20 Nov 2024